Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation

BACKGROUND: Mutated anaplastic lymphoma kinase (ALK) drives the development of advanced non-small cell lung cancer (NSCLC). Most reported small-molecule inhibitors targeting the ALK domain do not display good inhibition of the G1202R solvent front mutation. The solvent front mutation was assumed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Han, Wang, Yao, Guo, Wentao, Du, Bin, Huang, Xiaobing, Wu, Riping, Yang, Baoyu, Lin, Xiaoyan, Wu, Yilan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953303/
https://www.ncbi.nlm.nih.gov/pubmed/29785088
http://dx.doi.org/10.2147/DDDT.S147104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953303/
https://www.ncbi.nlm.nih.gov/pubmed/29785088
http://dx.doi.org/10.2147/DDDT.S147104

Ejemplares similares